European Group for Blood and Marrow Transplantation Risk Score Predicts the Outcome of Patients with Acute Leukemia Receiving Single Umbilical Cord Blood.

Slides:

Advertisements

Similar presentations

Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic.

Advertisements

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease Melanie N. Stauber,

Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk.

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia Lan-Ping Xu, Zheng-Li Xu, Xiao-Hui Zhang, Huan.

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Nonmalignant Late Effects in Survivors of Partially Matched Donor Hematopoietic Stem Cell Transplantation Xiao-Dong Mo, Lan-Ping Xu, Dai-Hong Liu, Xiao-Hui.

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan.

Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic.

Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral.

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Effects of Priming with Recombinant Human Granulocyte Colony–Stimulating Factor on Conditioning Regimen for High-Risk Acute Myeloid Leukemia Patients.

Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Comparison of Cord Blood Transplantation with Unrelated Bone Marrow Transplantation in Patients Older than Fifty Years Masatsugu Tanaka, Koichi Miyamura,

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission Daniela Damiani,

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Biology of Blood and Marrow Transplantation

Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage.

Benefit of Allogeneic Transplantation in Patients Age ≥ 60 Years with Acute Myeloid Leukemia Is Limited to Those in First Complete Remission at Time of.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute.

Sequential Intensified Conditioning and Tapering of Prophylactic Immunosuppressants for Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic Leukemia

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia Yu Wang,

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

Diarrhea during the Conditioning Regimen Is Correlated with the Occurrence of Severe Acute Graft-versus-Host Disease through Systemic Release of Inflammatory.

The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age Lujia Dong,

Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation Ibrahim.

T Cell–Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients with Central Nervous System Involvement Jun Aoki, Ken.

Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation Stefan O. Ciurea, Victor Mulanovich,

Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children Xiaojun.

Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and.

Blood and Marrow Transplant Handbook

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation:

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Mammen Chandy Biology of Blood and Marrow Transplantation

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia,

Mary Eapen Biology of Blood and Marrow Transplantation

Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease

Presentation transcript:

European Group for Blood and Marrow Transplantation Risk Score Predicts the Outcome of Patients with Acute Leukemia Receiving Single Umbilical Cord Blood Transplantation Xiaoyu Zhu, Lulu Huang, Changcheng Zheng, Baolin Tang, Huilan Liu, Liangquan Geng, Juan Tong, Lei Zhang, Xuhan Zhang, Wen Yao, Kaidi Song, Xingbing Wang, Kaiyang Ding, Zimin Sun Biology of Blood and Marrow Transplantation Volume 23, Issue 12, Pages 2118-2126 (December 2017) DOI: 10.1016/j.bbmt.2017.08.011 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (A) The projected 3-year OS was 65.0% (95% CI, 57.6% to 71.4%) and the projected 3-year LFS was 59.8% (95% CI, 52.1% to 66.7%). (B) The cumulative incidences of 3-year NRM and 3 year-relapse rate were 19.5% (95% CI, 14.2% to 25.5%) and 20.3% (95% CI, 14.6% to 26.7%), respectively. Biology of Blood and Marrow Transplantation 2017 23, 2118-2126DOI: (10.1016/j.bbmt.2017.08.011) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Evaluation of outcomes based on the EBMT risk score. (A) and (B) Projected OS of patients with EBMT risk scores of 1, 2, 3, and 4 to 6 were 81.7%, 72.2%, 58.1%, and 43.8%, respectively, after sUCBT (P = .00363), and the LFS of the patients with scores of 1, 2, 3, and 4 to 6 were 75.9%, 62.6%, 53.2%, and 44.3%, respectively, after sUCBT (P = .00823). (C) and (D) Cumulative incidences of 3-year NRM were 7.3%, 19.0%, 23.1%, and 31.7% (P = .0539) and of the 3-year relapse rate were 15.3%, 18.3%, 23.8%, and 23.9% (P = .408) for scores of 1, 2, 3, and 4 to 6, respectively. Biology of Blood and Marrow Transplantation 2017 23, 2118-2126DOI: (10.1016/j.bbmt.2017.08.011) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 After pooling patients into 4 scoring bins (0, 1, 2, and 3 to 5), the sUCBT-EBMT risk score is predictive for OS, LFS, NRM, and relapse rates. (A) and (B) Projected 3-year OS and LFS of patients with sUCBT-EMBT risk scores of 0, 1, 2, and 3 to 5 were 90.0%, 78.4%, 71.2%, and 28.5% (P < .0001) and 80.0%, 72.6%, 63.5%, and 26.2% (P < .0001), respectively, after sUCBT. (C) and (D) Cumulative incidences of NRM and relapse rate of patients with scores of 0, 1, 2, and 3 to 5 were .0%, 10.0%, 15.4%, and 46.3% (P < .0001) and 11.1%, 17.4%, 21.1%, and 27.2% (P = .33), respectively, after sUCBT. Biology of Blood and Marrow Transplantation 2017 23, 2118-2126DOI: (10.1016/j.bbmt.2017.08.011) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions